# Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis

> **NCT00770965** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 80 (actual)

## Conditions studied

- Chronic Plaque Psoriasis

## Interventions

- **BIOLOGICAL:** AIN457
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00770965
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09-10
- **Primary completion:** 2009-09-17
- **Final completion:** 2009-09-17
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2018-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00770965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00770965, "Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00770965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*